Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder - NCT00149799-02906 (Clinical Trial 128142)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy128142.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Providence |
|
State:
|
|
RI |
| Zip Code: |
|
02906 |
| Conditions: |
|
Anxiety Disorders - Somatoform Disorders |
| Purpose: |
|
This study will assess the relapse-prevention rate of escitalopram (Lexapro) in the
treatment of body dysmorphic disorder.
|
| Study summary: |
|
Body Dysmorphic Disorder (BDD) is a mental disorder in which a person is preoccupied by a
very slight physical anomaly or an imagined defect in his or her appearance. It is
associated with Obsessive Compulsive Disorder (OCD). Treatment of BDD usually reduces
symptoms of the disorder, but some people's symptoms regress only for a short time and then
reappear. Drugs that will reduce the risk of BDD-relapse are needed. Escitalopram, also
known as Lexapro, is a serotonin reuptake inhibitor (SRI). It is an oral drug used to treat
depression and general anxiety disorder. Its ability to prevent relapse of BDD has not yet
been studied. This study will evaluate the relapse-prevention rate of escitalopram for the
treatment of BDD.
The study will start with an open-label phase, during which all participants will receive
escitalopram for 14 weeks. Study visits will occur once weekly for the first month and once
every other week for the remainder of the 14 weeks. At the end of this initial phase, those
who show improvement will continue into a double-blind phase. The remaining participants
will be randomly assigned to receive either escitalopram or placebo for an additional 6
months. Study visits will occur once every other week, with an additional visit at Week 15.
Participants' improvement or return of BDD-related symptoms will be assessed. Throughout the
6 months, any participant showing relapse will be referred to alternate treatment. |
| Criteria: |
|
Inclusion Criteria:
- Outpatient men and women age 18 and older
- DSM-IV diagnosis of BDD within 6 months of study start date
- Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale
- Lives within driving distance of Boston, MA or Providence, RI
Exclusion Criteria:
- Suicidal or homicidal tendencies
- Alcohol/drug abuse or dependence within 3 months of study entry |
|
|
|
| Study is available at: |
|
Butler Hospital
Providence, RI 02906
United States
Primary Contact:
Phone: 401-455-6466
Secondary Contact:
Caitlin Taylor, BA
Email: bdd@partners.org
Phone: 1-877-4-MGH-BDD |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|